Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Herbert J. Zeh, Shikhar Uttam, Alessandro Paniccia, Melissa E. Hogg, Kevin McGrath, Adam Slivka, Vikram C. Gorantla, Rohit Das, Katelyn Smith, Roby Antony Thomas, Asif Khalid, Michael S. Landau, Kenneth E. Fasanella, Natalie Seiser, James F. Pingpank, Harkirat Singh, Nathan Bahary, Patrick Henn, Kenneth K. Lee, Brian K. Theisen, Melanie Ongchin, Savreet Sarkaria, Randall E. Brand, Aatur D. Singhi, Brian A. Boone, Amer H. Zureikat, Susannah G. Ellsworth, N. Paul Ohori, Anil K. Dasyam, Jennifer Chennat, Susan Shyu, John C. Rhee
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND & AIMS: The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current gradi
Publikováno v:
Annals of surgical oncology. 30(2)
Autor:
Amer H. Zureikat, Ibrahim Nassour, David L Bartlett, Annissa Desilva, Lance A. Liotta, Aatur D. Singhi, Virginia Espina, Alessandro Paniccia, Samer AlMasri, Nathan Bahary, Brian A. Boone, Herbert J. Zeh, Patricia Loughran, Michael T. Lotze, Mazen S. Zenati
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase resection rat
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
M.E. Hogg, Brian A. Boone, Kenneth K. Lee, Alessandro Paniccia, Nathan Bahary, Susannah G. Ellsworth, Amer H. Zureikat, Joal D. Beane, David L. Bartlett, Asmita Chopra, Michael T. Lotze, Aatur D. Singhi, Herbert J. Zeh, Adam C. Olson, Jacob C. Hodges, Steve Burton
Publikováno v:
Ann Surg Oncol
BACKGROUND. Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify